Minutia Wins $1.2M Grant from CIRM for “Immune Cloaking of Human Stem Cell-Derived Insulin Producing Cells”
From a CIRM press release.
Our tenant Minutia, with CEO and co-founder Katy Digovich listed as recipient, won a $1,192,586 DISC0 award for “Immune cloaking of human stem cell-derived insulin producing cells for curative cell therapy without immunosuppression.”
CIRM invests $25 million for discovery and preclinical research, Patient Support Program
The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded to fund numerous projects across the Agency’s discovery, clinical, and infrastructure programs.
The awards will support 11 projects in the Agency’s Foundation Awards (DISC 0) Program, which supports rigorous studies addressing critical basic knowledge gaps in the biology of stem cells and regenerative medicine approaches and to advance stem cell-based tools.
“CIRM is dedicated to the advancement of early-stage transformative therapies for prevalent health conditions such as heart disease”, said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM.
In addition, CIRM awarded $2.5 million to support the establishment of a Patient Support Program (PSP) to enhance patient access to CIRM-funded clinical trials, an important component of CIRM’s mission and Infrastructure Program.
